PHIO PHARMACEUTICALS INSIDER BUYING SPREE: Executives Stack Shares as Stock Hits 6% Insider Ownership Amid Tumultuous Market Conditions

Insider Buying Spree at PHIO: What It Signals for the Stock

On September 28, 2026, PHIO PHARMACEUTICALS CORP’s board member, Ronald Todd Plott, added 10,000 shares to his position through two back‑to‑back purchases, bringing his holdings to 42,000 shares. The trades were executed at roughly $1.04 per share—well below the market close of $1.03—indicating a slight premium that insiders often pay when they want to lock in gains or signal confidence. While the dollar amount is modest relative to the company’s $11.73 million market cap, the timing is notable: it follows a wave of high‑volume buying by senior executives, including CFO Lisa Carson Cabott and Chairman‑President Robert Bitterman, who each added hundreds of thousands of shares in the same filing.

Investor Takeaway: Insider Momentum vs. Volatility

Insider buying is traditionally viewed as a bullish signal because those with the most information feel confident enough to invest their own capital. In PHIO’s case, the cumulative insider purchases of 764 k shares by Bitterman, 189 k by Carson, and 42 k by Plott, represent a significant portion of the outstanding shares—roughly 6 % of the 1.3 million shares outstanding. When combined with the company’s recent 52‑week low of $0.81 and a steep 56 % year‑to‑date decline, this buying can help temper negative sentiment and may serve as a catalyst for a rebound, especially if the stock’s fundamentals improve.

That said, the broader market context is mixed. PHIO’s price‑earnings ratio is negative, reflecting a lack of earnings, and the company’s revenue pipeline is still evolving. The insider activity may be a defensive play—locking in value before a potential catalyst—rather than a bullish bet on future earnings. For investors, the lesson is to monitor subsequent filings for any shifts in volume or price, and to assess whether the insiders’ holdings are growing or shrinking.

Who Is Ronald Todd Plott? A Pattern of Confidence

Plott’s transaction history shows a steady accumulation of PHIO shares. In August 2026 he purchased 15 k shares at $1.14, and by September 28 his position had grown to 42 k shares through two purchases of 5 k each. Unlike some insiders who trade aggressively, Plott’s purchases have been modest and incremental, suggesting a long‑term investment thesis rather than a short‑term trading strategy. His buying at a price slightly above the closing price indicates willingness to pay a small premium, which could be interpreted as an endorsement of the company’s strategic direction, especially following the recent amendment to the long‑term incentive plan that increased the pool of available shares.

Historically, Plott has not been involved in large sell transactions, and his holdings have increased steadily over the past year. This pattern aligns with a belief in PHIO’s oncology and immunotherapy pipeline, which the company continues to develop despite the competitive biotech landscape.

What Could Come Next? Catalysts and Risks

Looking ahead, PHIO’s upcoming regulatory filings on its cancer immunotherapy candidates could act as a catalyst. A positive study result or FDA clearance would likely drive the stock upward, reinforcing the insiders’ confidence. Conversely, any adverse regulatory action or setbacks in clinical trials could prompt a sell‑off, potentially eroding the gains from recent insider buying. The company’s relatively low market cap and negative P/E also mean that it is highly susceptible to short‑term market swings.

In sum, the recent insider buying spree, led by Plott alongside CFO and CEO purchases, signals a cautiously optimistic stance from key executives. For investors, it offers a signal of potential upside, but one that should be weighed against the company’s current earnings profile, pipeline status, and the broader biotech market environment.